Note: This medical device record is a PMA supplement. A supplement may have changed the device description/function or indication from that approved in the original PMA. Be sure to look at the original PMA record for more information. |
|
Device | PD-L1 IHC 22C3 pharmDx |
Generic Name | Immunohistochemistry assay, antibody, programmed death-ligand 1 |
Applicant | Agilent Technologies, Inc. 5301 Stevens Creek Blvd Santa Clara, CA 95051 |
PMA Number | P150013 |
Supplement Number | S023 |
Date Received | 11/17/2021 |
Decision Date | 11/23/2021 |
Product Code |
PLS |
Advisory Committee |
Pathology |
Supplement Type | Special (Immediate Track) |
Supplement Reason | Labeling Change - Indications/instructions/shelf life/tradename |
Expedited Review Granted? | No |
Combination Product | No |
Approval Order Statement Approved the removal of the urothelial carcinoma (UC) indication from the device intended use statement and labeling. |
|
|